PHP
AVDL

Parkman Healthcare Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Parkman Healthcare Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-254,827
Closed -$3.34M – 94
2024
Q3 		$3.34M Sell
254,827
-123,462
-33% -$1.88M 0.43% 62
2024
Q2 		$5.32M Sell
378,289
-9,481
-2% -$155K 0.71% 51
2024
Q1 		$6.55M Buy
+387,770
New +$5.77M 0.8% 44

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Parkman Healthcare Partners's AVDL Position: Q4 2024 in Review

Parkman Healthcare Partners sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 254,827 shares — an estimated $3.34M sold.

Parkman Healthcare Partners first reported a position in AVDL in Q1 2024 and held it in 3 quarters. The position peaked at $6.55M in Q1 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Parkman Healthcare Partners reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 254,827 Avadel Pharmaceuticals shares in Q4 2024, an estimated $3.34M.
  • Parkman Healthcare Partners first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Parkman Healthcare Partners's Avadel Pharmaceuticals position peaked at $6.55M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.